I'm looking at the clear evidence of accumulation. Volume is steadily rising along with the share price. By the end of this month alot of data will have already been collected on the patient that had the 100k cell injection. I recall after the third week it is usually very evident what is happening. If Gary is alluding to this being the appropriate commercialized dose (100k) it is going to yield some very evident conclusive results that will likely be shared with us at the cc.
We will also be injecting 2 more patients this month any day now, plus Korea is at the starting gate. As of this moment, it seems we are not approved for multiple blebs, but I agree 100% with Stockfodder that we are doing concurrent animal studies as we speak on multiple blebs at the 100-200k cell range, and will be presenting data to the FDA for protocol change in Phase 2/3 if it proves to be the best way to distribute the cells. We are ALREADY BATTING 1000, but we are trying to improve the effect on visual restoration, which is the Holy Grail that no other treatment has been found to do at any degree. Remember that tidbit if you are thinking about trading and not investing.
In the back of my mind, I always think about Gary's ability and years of training in order to make money as a hedgefund manager. That is one of THE most lucrative professions on the planet. They are trained to make the most return with trying to minimize their risk. That is why if Gary is going to list us on the Nasdaq IMO he will not just be coupling it with stellar results it will be something along the lines of a partnership or an new IND. He missed his window with the Russell reshuffling, so he has 5 1/2 months remaining this year to impliment the change. Over that period of time, we will have accumulated alot of data on newly injected patients at higher doses, as well as data on the patients injected over a year ago. At some point, big pharma is going to make us an offer much larger than Cephalon did with Mesoblast, because our market size is massively larger, and they were not going after the number one unmet medical disease without any competition. It's going to be a number that will most definitely be in the record books as far as stem cell companies. We will set the bar. Top CSO+top institutions involved with trial+top BOD+top eye surgeons backing us+providing a CURE for number one unmet medical disease+batting 1000+very disruptive to others in the field+will cost big pharma billions in lost revenue as their therapy for wet AMD is lost=Billions Stay the course. GLTA